Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Questcor Pharmaceuticals



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.5%. By the end of trading, Questcor Pharmaceuticals fell $2.45 (-3.0%) to $79.05 on average volume. Throughout the day, 3,951,964 shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 3,046,600 shares. The stock ranged in price between $76.35-$82.53 after having opened the day at $82.22 as compared to the previous trading day's close of $81.50. Other companies within the Drugs industry that declined today were:

OncoGenex Pharmaceuticals



), down 60.3%,

Transition Therapeutics



), down 12.3%,




), down 10.4% and

Arrowhead Research



), down 9.8%.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of autoimmune and inflammatory disorders. The company primarily offers H.P. Questcor Pharmaceuticals has a market cap of $5.0 billion and is part of the health care sector. The company has a P/E ratio of 13.7, below the S&P 500 P/E ratio of 17.7. Shares are up 49.7% year to date as of the close of trading on Friday. Currently there are 4 analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Questcor Pharmaceuticals

as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front,

Furiex Pharmaceuticals



), up 28.6%,




), up 19.5%,

ProPhase Labs



), up 13.1% and




), up 12.2% , were all gainers within the drugs industry with




) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.